Allakos Provides Business Update and Reports Third Quarter 2024 Financial Results
November 06, 2024 16:02 ET
|
Allakos Inc.
SAN CARLOS, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and...
Allakos Announces Phase 1 Trial Results of Subcutaneous AK006 in Healthy Volunteers
October 10, 2024 16:02 ET
|
Allakos Inc.
– Subcutaneously administered AK006 showed approximately 77% bioavailability and prolonged receptor occupancy on mast cells –– Subcutaneous AK006 was well-tolerated with a favorable safety profile ––...
Allakos Provides Business Update and Reports Second Quarter 2024 Financial Results
August 07, 2024 16:02 ET
|
Allakos Inc.
SAN CARLOS, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and...
Allakos Announces Positive Results from its Ongoing Phase 1 Trial of AK006 in Healthy Volunteers, with AK006 Demonstrating High Receptor Occupancy on Mast Cells and a Favorable Safety Profile
June 25, 2024 16:02 ET
|
Allakos Inc.
– AK006 achieved serum concentrations consistent with levels demonstrating inhibitory activity in preclinical experiments –– Skin biopsies from subjects treated with AK006 show high receptor occupancy...
Allakos Announces First Patient Dosed in Phase 1 Trial of AK006 in Chronic Spontaneous Urticaria
May 28, 2024 07:02 ET
|
Allakos Inc.
– Top-line Phase 1 CSU results expected at year end 2024 – SAN CARLOS, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing AK006 for the...
Allakos Provides Business Update and Reports First Quarter 2024 Financial Results
May 09, 2024 16:02 ET
|
Allakos Inc.
SAN CARLOS, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and...
Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
March 14, 2024 16:02 ET
|
Allakos Inc.
SAN CARLOS, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and...
Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024
February 26, 2024 07:02 ET
|
Allakos Inc.
– Atopic dermatitis and prurigo nodularis skin lesions show evidence of MRGPRX2 mast cell activation and activated macrophages – – AK006 inhibited mast cell activation and reduced mast cell numbers...
Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition
February 12, 2024 07:02 ET
|
Allakos Inc.
– Data provide insights on the signaling pathways involved with AK006 mast cell inhibition –– AK006 has a distinct mechanism of action that leads to broad inhibitory effects on mast cells – SAN...
Allakos Announces a Restructuring to Focus on Development of AK006
January 16, 2024 07:02 ET
|
Allakos Inc.
Existing cash to fund planned ongoing operations into mid-2026AK006 is being tested in a comprehensive Phase 1 clinical program, including: ongoing single and multiple ascending dose trial in healthy...